Rucaparib
A PARP inhibitor used to treat BRCA-mutated ovarian and breast cancers, working by blocking DNA repair enzymes that cancer cells with BRCA mutations depend on for survival. This targeted approach causes cancer cells to accumulate lethal DNA damage while having less effect on normal cells.
Masse moléculaire
323,4000 g/mol
LogP
2,50
TPSA
56,90 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.
Structure 2D
Cite this structure
Embed this structure
SMILES
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1
InChI
InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)
Molecular Formula
C19H18FN3O
HBD / HBA
3 / 3
Liaisons Rotatives
3
Atomes Lourds
24
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A PARP inhibitor used to treat BRCA-mutated ovarian and breast cancers, working by blocking DNA repair enzymes that cancer cells with BRCA mutations depend on for survival. This targeted approach causes cancer cells to accumulate lethal DNA damage while having less effect on normal cells.
Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.
Yes, Rucaparib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1173055. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9931954. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="rucaparib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/rucaparib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/rucaparib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/rucaparib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="rucaparib"></drugfyi-drug>